Inission (INISS) ABGSC Investor Days summary
Event summary combining transcript, slides, and related documents.
ABGSC Investor Days summary
11 Jan, 2026Company overview and structure
Operates as both an EMS contract manufacturer and an OEM through Enedo, organized into business areas with a strong value-driven culture.
Comprises nine factories and six companies, with a focus on proximity to customers, mainly in the Nordics.
Acquisitions are central to growth, averaging about one per year, with the latest being AXXE in Norway.
Enedo, a Finnish-Italian product company, is being integrated, with its Tunis factory transitioning to EMS operations by early Q2 next year.
Market position and customer base
Specializes in high-mix, low-volume industrial electronics, serving complex product needs in smaller batches.
Customer base is diversified, with no overreliance on a single client; largest account is ABB at about 10% of EMS sales.
Enedo’s customers are large multinationals, offering potential for future growth.
Acquisition strategy and integration
Acquisition targets are chosen for complementary customer portfolios, management, culture, financial health, and geography.
Synergies are realized post-acquisition, but not factored into initial pricing.
Current focus is on expanding geographically into Denmark, northern Germany, and Poland.
Enedo is expected to pursue acquisitions in 1–2 years after further stabilization.
Latest events from Inission
- 2025 revenue rose to SEK 2,206.2 million, with strong cash flow and positive 2026 outlook.INISS
Q4 202520 Feb 2026 - Q2 sales up 1.4% to 570 MSEK, but organic growth and margins declined.INISS
Q2 202423 Jan 2026 - Sales and EBIT fell, but order intake and stability improved; guidance and cost base adjusted.INISS
Q3 202415 Jan 2026 - Sales and margins fell, but order intake and cash flow rebounded; cost cuts and recovery expected.INISS
Q4 202426 Dec 2025 - Targeting 15% annual growth and 9% EBITDA margin, leveraging acquisitions and mega trends.INISS
CMD 202529 Nov 2025 - Order intake up, sales and profit down; cost cuts and Nasdaq listing shape cautious outlook.INISS
Q1 & AGM 202526 Nov 2025 - Sales fell 6.2%, but order intake, cash flow, and acquisitions signal H2 recovery.INISS
Q2 202523 Nov 2025 - Q3 sales and margins improved, EMS strong, Enedo restructuring, 2025 targets revised.INISS
Q3 20257 Nov 2025